The threshold rate of oral atypical anti-psychotic adherence at which paliperidone palmitate is cost saving

References

• Velligan DI, Weiden PJ, Sajatovic M, et al. Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines. J Psychiatr Pract 2010;16:306-24
   PubMed Web of Science ®Google Scholar
• Beck EM, Cavelti M, Kvrgic S, et al. Are we addressing the 'right stuff' to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication. Schizophr Res 2011;132:42-9
   PubMed Web of Science ®Google Scholar
• Glazer WM, Byerly MJ. Tactics and technologies to manage nonadherence in patients with schizophrenia. Curr Psychiatry Rep 2008;10:359-69
   PubMedGoogle Scholar
• Baloush-Kleinman V, Levine SZ, Roe D, et al. Adherence to antipsychotic drug treatment in early-episode schizophrenia: a six-month naturalistic follow-up study. Schizophr Res 2011;130:176-81
   PubMed Web of Science ®Google Scholar
• Goff DC, Hill M, Freudenreich O. Treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry 2011;72:e13
   PubMedGoogle Scholar
• Kane JM, Garcia-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections. Br J Psychiatry Suppl 2009;52:S63-7
   PubMedGoogle Scholar
• Glazer WM. Who receives long-acting antipsychotic medications? Psychiatr Serv 2007;58:437
   PubMedGoogle Scholar
• Lieberman JA. Neurobiology and the natural history of schizophrenia. J Clin Psychiatry 2006;67:e14
   PubMedGoogle Scholar
• Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96
   PubMed Web of Science ®Google Scholar
• Lieberman J, Chakos M, Wu H, et al. Longitudinal study of brain morphology in first episode schizophrenia. Biol Psychiatry 2001;49:487-99
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Perkins D, Belger A, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 2001;50:884-97
   PubMed Web of Science ®Google Scholar
• Robinson DG, Woerner MG, McMeniman M, et al. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 2004;161:473-9
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Schooler NR, Weedon JC, et al. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. J Clin Psychiatry 2009;70:1397-406
   PubMed Web of Science ®Google Scholar
• Adams CE, Fenton MK, Quraishi S, et al. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001;179:290-9
   PubMed Web of Science ®Google Scholar
• Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophrenia - a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 2011;127:83-92
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S (eds.). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. Accessed December 19, 2011
   Google Scholar
• Kelin K, Brnabic AJM, Newton R, et al. Baseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherence. Patient Prefer Adherence 2010;4:301-11
   PubMed Web of Science ®Google Scholar
• Shi L, Ascher-Svanum H, Zhu B, et al. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv 2007;58:482-8
   PubMed Web of Science ®Google Scholar
• Davis JM, Matalon L, Watanabe MD, et al. Depot antipsychotic drugs. Place in therapy. Drugs 1994;47:741-73
   Google Scholar
• Kikkert MJ, Koeter MW, Dekker JJ, et al. The predictive validity of subjective adherence measures in patients with schizophrenia. Int J Methods Psychiatr Res 2011;20:73-81
   PubMed Web of Science ®Google Scholar
• Glazer WM, Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients. J Clin Psychiatry 1996;57:337-45
   PubMed Web of Science ®Google Scholar
• Edwards NC, Locklear JC, Rupnow MF, et al. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics 2005;23(1 Suppl):75-89
   PubMedGoogle Scholar
• Edwards NC, Rupnow MF, Pashos CL, et al. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US. Pharmacoeconomics 2005;23:299-314
   PubMed Web of Science ®Google Scholar
• Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model. Curr Med Res Opin 2011;27:713-30
   PubMed Web of Science ®Google Scholar
• Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. Cost Eff Resour Alloc 2009;7:4
   PubMedGoogle Scholar
• Diaz E, Levine HB, Sullivan MC, et al. Use of the Medication Event Monitoring System to estimate medication compliance in patients with schizophrenia. J Psychiatry Neurosci 2001;26:325-9
   PubMed Web of Science ®Google Scholar
• Olfson M, Mechanic D, Hansell S, et al. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000;51:216-22
   PubMed Web of Science ®Google Scholar
• Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-7
   PubMed Web of Science ®Google Scholar
• Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998;49:196-201
   PubMed Web of Science ®Google Scholar
• Gutiérrez Casares JR, Cañas F, Rodríguez-Morales A, et al. Adherence to treatment and therapeutic strategies in schizophrenic patients: the ADHERE study. CNS Spectr 2010;15:327-37
   PubMedGoogle Scholar
• Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63:892-909
   PubMed Web of Science ®Google Scholar
• Hogarty GE, Ulrich RF. Temporal effects of drug and placebo in delaying relapse in schizophrenic outpatients. Arch Gen Psychiatry 1977;34:297-301
   PubMed Web of Science ®Google Scholar
• Davis JM, Dysken MW, Haberman SJ, et al. Use of survival curves in analysis of antipsychotic relapse studies. Adv Biochem Psychopharmacol 1980;24:471-81
   PubMedGoogle Scholar
• Weiden PJ, Dixon L, Frances AJ, et al. Neuroleptic noncompliance in schizophrenia. In: Tamminga CA, Schultz SC, eds. Advances in neuropsychiatry and psychopharmacology: schizophrenia research. 1. New York, NY: Raven Press, 1991. p 285-96
   Google Scholar
• Nicholl D, Akhras KS, Diels J, et al. Burden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspective. Curr Med Res Opin 2010;26:943-55
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
   PubMed Web of Science ®Google Scholar
• Pandina G, Lane R, Gopal S, et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:218-26
   PubMed Web of Science ®Google Scholar
• IMS Health NPA Retail + IMS NSP Non-Retail volume calculated into Days of Therapy to appropriately measure growth long-acting; 3rd Quarter, 2010; Wolters Kluwer and Premier
   Google Scholar
• Wolters Kluwer Source Lx (APLD) Database 8/1/2010 - 7/31/2011 data for patients with a schizophrenia diagnosis
   Google Scholar
• Invega Sustenna Prescribing Information. http://www.invegasustenna.com/pdf/invegasustenna–prescribing–info.pdf. Accessed December 19, 2011
   Google Scholar
• Keith S. Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness. Expert Rev Neurother 2009;9:9-31
   PubMed Web of Science ®Google Scholar
• Edwards NC, Pesa J, Meletiche DM, et al. One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia. Curr Med Res Opin 2008;24:3341-55
   PubMed Web of Science ®Google Scholar
• Lindström E, Eberhard J, Fors BM, et al. A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden. Nord J Psychiatry 2011;65(6):403-13
   PubMed Web of Science ®Google Scholar
• King D, Knapp M, Thomas P, et al. Cost-effectiveness analysis of aripiprazole vs standard-of-care in the management of community-treated patients with schizophrenia: STAR study. Curr Med Res Opin 2011;27:365-74
   PubMed Web of Science ®Google Scholar
• Cocchi A, Mapelli V, Meneghelli A, et al. Cost-effectiveness of treating first-episode psychosis: five-year follow-up results from an Italian early intervention programme. Early Interv Psychiatry 2011;5:203-11
   PubMedGoogle Scholar
• Peng X, Ascher-Svanum H, Faries DE, et al. Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy. Clinicoecon Outcomes Res 2011;3:79-87
   PubMedGoogle Scholar
• Kasteng F, Eriksson J, Sennfält K, et al. Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder. Acta Psychiatr Scand 2011;12:214-25
   Google Scholar
• Goff DC, Hill M, Freudenreich O. Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry 2010;71(2 Suppl):20-6
   PubMedGoogle Scholar